Diabetes: Preventing type 2 diabetes mellitus: Is metformin the answer?

Nature Reviews Endocrinology

Volumn 6, Issue 5, 2010, Pages 253-254

  Buchanan, Thomas A ^a   Xiang, Anny H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Kaiser Permanente Southern California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

B LYMPHOCYTE; BODY MASS; DIABETIC OBESITY; DISEASE COURSE; FAT BODY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; METFORMIN;

EID: 77951686647     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.25     Document Type: Short Survey

References (10)

1. Nathan, D. M. et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30, 753-759 (2007).
2. Rhee, M. K. et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care 33, 49-54 (2010).
3. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
4. Buchanan, T. A. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51, 2796-2803 (2002).
5. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 368, 1096-1105 (2006).
6. Chaisson, J. L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002).
7. Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjöström, L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155-161 (2004). (Pubitemid 38196725)
8. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26, 977-980 (2003).
9. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001). (Pubitemid 32378388)
10. Xiang, A. et al. Effect of pioglitazone on pancreatic beta cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517-522 (2006).